Septerna Inc. (SEPN)
NASDAQ: SEPN
· Real-Time Price · USD
6.51
-0.65 (-9.08%)
At close: May 06, 2025, 1:24 PM
-9.08% (1D)
| Bid | 5 |
| Market Cap | 302.75M |
| Revenue (ttm) | 539K |
| Net Income (ttm) | -17.24M |
| EPS (ttm) | -7.26 |
| PE Ratio (ttm) | -0.9 |
| Forward PE | -2.38 |
| Analyst | Buy |
| Ask | 8.35 |
| Volume | 92,071 |
| Avg. Volume (20D) | 520,978 |
| Open | 7.01 |
| Previous Close | 7.16 |
| Day's Range | 6.49 - 7.03 |
| 52-Week Range | 4.17 - 28.99 |
| Beta | 4.26 |
About SEPN
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Prog...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 25, 2024
Employees 75
Stock Exchange NASDAQ
Ticker Symbol SEPN
Website https://septerna.com
Analyst Forecast
According to 4 analyst ratings, the average rating for SEPN stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 483.72% from the latest price.
Stock Forecasts2 months ago
-46.99%
Septerna shares are trading lower after the compan...
Unlock content with
Pro Subscription
